Her2/neu expression in poorly-differentiated and anaplastic thyroid carcinomas

Anticancer Research

Volumn 23, Issue 3 B, 2003, Pages 2349-2353

  Ensinger, Christian ^a   Prommegger, Rupert ^a   Kendler, Dorotha ^a   Gabriel, Michael ^a   Spizzo, Gilbert ^a   Mikuz, Gregor ^a   Kremser, Roswitha ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Anaplastic; Her2 neu; Immunohistochemistry; Poorly differentiated; Thyroid cancer

Indexed keywords

FORMALDEHYDE; MONOCLONAL ANTIBODY; ONCOPROTEIN; ONCOPROTEIN AB 17; PARAFFIN; UNCLASSIFIED DRUG;

ANALYSIS OF VARIANCE; ANAPLASTIC CARCINOMA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE C ERB; ONCOGENE C ERBB 2; ONCOGENE NEU; PRIORITY JOURNAL; STAINING; STATISTICAL ANALYSIS; THYROID CARCINOMA; TUMOR CELL; TUMOR DIFFERENTIATION;

CARCINOMA; CELL DIFFERENTIATION; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; THYROID NEOPLASMS;

EID: 0042703889     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Cooper GM (ed): The Cell, A Molecular Approach. Washington DC, ASM Press, 1997.
2. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW and Heiss MM: C-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 18: 2201-2209, 2000.
3. Stern DF, Heffernan PA and Weinberg RA: P185, a product of the neu proto-oncogene, is a receptor-like protein associated with tyrosine kinase activity. Mol Cell Biol 6: 1729-1740, 1986.
4. Hung MC and Lau YK: Basic science of HER-2/neu: a review. Semin Oncol 26: 51-59, 1999.
5. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL and Marks P: Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087-4091, 1990.
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
7. Zhang X, Silva E, Gershenson D and Hung MC: Amplification and rearrangement of c-erb B proto-oncogenes in cancer of human female genital tract. Oncogene 4: 985-989; 1989.
8. Schneider PM, Hung MC, Chiocca SM, Manning J, Zhao XY, Fang K and Roth JA: Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res 49: 4968-4971, 1989.
9. Chazin VR, Kaleko M, Miller AD and Slamon DJ: Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 7: 1859-1866, 1992.
10. Tan M, Yao J and Yu D: Overexpression of the c-erb-2 gene enhanced intrindic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 57: 1199-1205, 1997.
11. Yu D, Wang SS, Dulski KM, Tsai CM, Nicolson GL and Hung MC: C-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res 54: 3260-3266, 1994.
12. Hou L, Shi D, Tu SM, Zhang HZ, Hung MC and Ling D: Oral cancer progression and c-erbB-2/neu proto-oncogene expression. Cancer Lett 65: 215-220, 1992.
13. Weiner DB, Nordberg J, Robinson R, Nowell PC, Gazdar A, Greene MI, Williams WV, Cohen JA and Kern JA: Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Res 50: 421-425, 1990.
14. Xia W, Lau YK, Zhang HZ, Liu AR, Li L, Kiyokawa N, Clayman GL, Katz RL and Hung MC: Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res 3: 3-9, 1997.
15. Yokota J, Yamamoto T, Miyajima N, Toyoshima K, Nomura N, Sakamoto H, Yoshida T, Terada M and Sugimura T: Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 2: 283-287, 1988.
16. Yoshida K, Tsuda T, Matsumura T, Tsujino T, Hattori T, Ito H and Tahara E: Amplification of epidermal growth factor receptor (EGFR) gene and oncogenes in human gastric carcinomas. Virchows Arch B Cell Pathol Incl Mol Pathol 57: 285-290, 1989.
17. Yu DH and Hung MC: Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. Oncogene 6: 1991-1996, 1991.
18. Kremser R, Obrist P, Spizzo G, Erler H, Kendler D, Kemmler G, Mikuz G and Ensinger C: Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease. Virchows Arch: in press, 2003.
19. Hedinger C, Williams ED and Sobin LH: The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer 63: 908-911, 1989.
20. Rosai J (ed), Carcangiu ML and DeLellis RA: Tumors of the Thyroid Gland (Atlas of Tumor Pathology, Third Series, Fascicle 5). Washington D.C., Armed Forces Institute of Pathology, 1992.
21. Lemoine NR, Wyllie FS, Lillehaug JR, Staddon SL, Hughes CM, Aasland R, Shaw J, Varhaug JE, Brown CL and Gullick WJ: Absence of abnormalities of the c-erbB-1 and c-erbB-2 proto-oncogenes in human thyroid neoplasia. Eur J Cancer 26: 777-779, 1990.
22. Akslen LA, Myking AO, Salvesen H and Varhaug JE: Prognostic impact of EGF-receptor in papillary thyroid carcinoma. Br J Cancer 68: 808-812, 1993.
23. Sugg SL, Ezzat S, Zeng L, Rosen IB, Freeman JL and Asa SL: Cytoplasmic staining of erbB-2 but not mRNA levels correlates with differentiation in humanthyroid neoplasia. Clin Endocrinol 49: 629-637, 1998.
24. Akslen LA and Varhaug JE: Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival. Cancer 76: 1643-1654, 1995.
25. Soda G, Antonaci A, Bosco D, Nardoni S and Melis M: Expressionof bcl-2, c-erbB-2, p53 and p21 (waf1-cip1) protein in thyroid carcinomas. J Exp Clin Cancer Res 18: 363-367, 1999.
26. Haugen DR, Akslen LA, Varhaug JE and Lillehaug JR: Expression of c-erbB-2 protein in papillary thyroid carcinomas. Br J Cancer 65: 832-837, 1992.
27. Utrilla JC, Martin-Lacave I, San Martin MV, Fernandez-Santos JM and Galera-Davidson H: Expression of c-erbB-2 oncoprotein in human thyroid tumours. Histopathology 34: 60-65, 1999.
28. De Potter CR, Van Daele S, Van de Vijver MJ, Pauwels C, Maertens G, De Boever J, Vandekerckhove D and Roels H: The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues. Histopathology 15: 351-362, 1989.
29. Coombs LM, Pigott DA, Sweeney E, Proctor AJ, Eydmann ME, Parkinson C and Knowles MA: Amplification and overexpression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 63: 601-608, 1991.
30. Soares P, Sambade C and Sobrinho-Simoes M: Expression of C-erb B2 in tumours and tumour-like lesions of the thyroid. Int J Cancer 56: 459-461, 1994.
31. Daneker G, Mercurio A, Guerra L, Wolf B, Salem R, Bagli D and Steele G: Laminin expression in colorectal carcinomas varying in degree of differentiation. Arch Surg 122: 1470-1474, 1987.
32. Kornilova T, Taverna D, Hoeck W and Hynes NE: Surface expression of erb B2 protein is post-transcriptionally regulated in mammary epithelial cells by epidermal growth factor and by the culture density. Oncogene 7: 511-519, 1992.
33. Revillion F, Bonneterre J and Peyrat JP: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34: 791-808, 1998.